NCT00835185View on ClinicalTrials.gov

Study of IMC-11F8 in Participants With Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

October 31, 2010

Conditions
Metastatic Colorectal Cancer
Interventions
BIOLOGICAL

IMC-11F8 (necitumumab)

IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1

DRUG

Oxaliplatin

Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1

DRUG

Folinic acid (FA)

FA 400 mg/m² IV infusion bolus injection

DRUG

5-FU

5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours

Trial Locations (5)

1000

ImClone Investigational Site, Brussels

7100

ImClone Investigational Site, Haine-Saint-Paul

28040

ImClone Investigational Site, Madrid

46010

ImClone Investigational Site, Valencia

08035

ImClone Investigational Site, Barcelona

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00835185 - Study of IMC-11F8 in Participants With Colorectal Cancer | Biotech Hunter | Biotech Hunter